Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa in Cardiac Arrest
NCT00999583Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2009
- Primary completion
- Jul 2013
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of epoetin alfa in cardiac arrest (SCA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients reaching Cerebral Performance Category level 1 at 60 days. Started Oct 2009; status: completed.
02
Drugs
epoetin alfa
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT00999583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00999583.